DBV Technologies S.A. (DBVT) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of DBV Technologies S.A. (NASDAQ:DBVT) from a hold rating to a buy rating in a research report report published on Tuesday morning. They currently have $50.00 target price on the stock.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
A number of other analysts have also commented on the stock. Leerink Swann lifted their price target on shares of DBV Technologies from $54.00 to $60.00 and gave the stock an outperform rating in a research note on Friday, August 25th. BidaskClub upgraded shares of DBV Technologies from a hold rating to a buy rating in a research note on Tuesday, August 22nd. ValuEngine upgraded shares of DBV Technologies from a sell rating to a hold rating in a research note on Thursday, July 13th. Morgan Stanley reiterated an overweight rating on shares of DBV Technologies in a research note on Monday, July 10th. Finally, HC Wainwright reiterated a buy rating and issued a $50.00 price target on shares of DBV Technologies in a research note on Thursday, July 6th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $50.00.
DBV Technologies (DBVT) opened at 44.16 on Tuesday. The stock’s market capitalization is $2.03 billion. The firm has a 50-day moving average of $43.75 and a 200-day moving average of $37.14. DBV Technologies has a 1-year low of $31.87 and a 1-year high of $46.33.
WARNING: “DBV Technologies S.A. (DBVT) Upgraded at Zacks Investment Research” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/dbv-technologies-s-a-dbvt-upgraded-at-zacks-investment-research/1535997.html.
Several hedge funds have recently made changes to their positions in DBVT. Dynamic Technology Lab Private Ltd acquired a new position in DBV Technologies during the second quarter worth about $222,000. Janus Henderson Group PLC acquired a new position in DBV Technologies during the second quarter worth about $90,724,000. Sectoral Asset Management Inc increased its position in DBV Technologies by 34.2% in the second quarter. Sectoral Asset Management Inc now owns 179,152 shares of the company’s stock worth $6,398,000 after buying an additional 45,653 shares during the last quarter. Airain ltd acquired a new position in DBV Technologies during the second quarter worth about $333,000. Finally, Jennison Associates LLC increased its position in DBV Technologies by 86.4% in the second quarter. Jennison Associates LLC now owns 1,002,067 shares of the company’s stock worth $35,784,000 after buying an additional 464,341 shares during the last quarter. Hedge funds and other institutional investors own 45.52% of the company’s stock.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with Analyst Ratings Network's FREE daily email newsletter.